Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis

A subunit antigenoid vaccine, Ac NFU1 (S-) MRC, was used to prevent primary herpes genitalis in 60 subjects considered to be at risk of this infection. There was no evidence of serious local or general side effects. Neutralising antibody responses were detected in 59% and 90% of subjects receiving t...

Full description

Saved in:
Bibliographic Details
Published in:British journal of venereal diseases 1982-12, Vol.58 (6), p.381-386
Main Authors: Skinner, G R, Woodman, C B, Hartley, C E, Buchan, A, Fuller, A, Durham, J, Synnott, M, Clay, J C, Melling, J, Wiblin, C, Wilkins, J
Format: Article
Language:English
Subjects:
Adult
Antibodies, Viral - biosynthesis
Dose-Response Relationship, Immunologic
Female
Herpes Genitalis - prevention & control
Humans
Immunodiffusion
Male
Neutralization Tests
Peptides - analysis
Simplexvirus - immunology
Vaccination - adverse effects
Viral Vaccines - immunology
Viral Vaccines - isolation & purification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A subunit antigenoid vaccine, Ac NFU1 (S-) MRC, was used to prevent primary herpes genitalis in 60 subjects considered to be at risk of this infection. There was no evidence of serious local or general side effects. Neutralising antibody responses were detected in 59% and 90% of subjects receiving the low and high doses of vaccine respectively; immunoprecipitating antibody was detected at a lower frequency, namely in 23% and 43% of subjects receiving the low and high doses respectively. After a mean follow-up period of 18 months none of the vaccinated subjects contracted herpes genitalis after completing the vaccination course.
ISSN:0007-134X
1368-4973
1472-3263
DOI:10.1136/sti.58.6.381